

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HESAI

Hesai Group

禾賽科技*

(A company controlled through weighted voting rights and incorporated in the Cayman Islands with limited liability)

(HKEX Stock Code: 2525)

(NASDAQ Stock Ticker: HSAI)

(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that, with effect from December 24, 2025:

- (1) Dr. CHEN Jie (陳劼) has resigned as an independent non-executive Director and a member of each of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee; and
- (2) Dr. WANG Hui (王慧) has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee.

Following the resignation and appointment of the relevant Directors, with effect from December 24, 2025, the composition of the Board committees has been changed.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Hesai Group (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. CHEN Jie (陳劼) (“**Dr. CHEN**”) has resigned as an independent non-executive Director and a member of each of the audit committee (the “**Audit Committee**”), the compensation committee (the “**Compensation Committee**”) and the Nominating and Corporate Governance Committee (the “**Nominating and Corporate Governance Committee**”) of the Company with effect from December 24, 2025 due to her other business commitments.

Dr. CHEN has confirmed that she has no disagreement with the Board and there is no matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its gratitude to Dr. CHEN for her valuable efforts and contributions to the Company during her tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Following Dr. CHEN's resignation, the Board is pleased to announce that Dr. WANG Hui (王慧) ("**Dr. WANG**") has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee with effect from December 24, 2025.

The biographical details of Dr. WANG are as follows:

Dr. WANG, aged 67, has been serving as an independent director of Beijing FJR Opto-electronic Technology Co., Ltd. (SSE: 688272) since September 2020. She also served as an independent director of Arcsoft Corporation Limited (SSE: 688088) from January 2019 to December 2024. In addition, she taught at the Peking University Law School from 1992 to 2018, most recently as an associate professor.

Dr. WANG obtained her Ph.D. degree in international economics law and a master's degree in international law from Peking University Law School in June 1992 and July 1988, respectively. She also obtained her bachelor of arts degree from Peking University in July 1984.

Dr. WANG has entered into an appointment letter with the Company for an initial term of 3 years or until the third annual general meeting of the Company after the Company's listing on The Stock Exchange of Hong Kong Limited, whichever is sooner. She is subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the second amended and restated memorandum and articles of association of the Company. Dr. WANG is entitled to a total remuneration package equivalent to USD100,000 per annum, which has been determined by the Board with reference to her duties and responsibilities as well as the prevailing market conditions.

Dr. WANG has confirmed with the Company (i) her independence as regards each of the factors referred to in Rule 3.13 of the Listing Rules, (ii) that she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) that there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, as at the date of this announcement, Dr. WANG does not (i) hold any other position in the Company or any of its subsidiaries or hold any directorship in other listed public companies in Hong Kong or overseas in the three years immediately preceding her appointment; (ii) have other relationships with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; (iii) have any other interests or short positions in the shares, the underlying shares or debentures of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); and (iv) have any other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, or any other matter relating to her appointment that needs to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Dr. WANG for joining as a member of the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the resignation and appointment of the relevant Directors above, the composition of the Board committees has been changed with effect from December 24, 2025.

By Order of the Board
Hesai Group
Dr. Yifan Li
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Hong Kong, December 24, 2025

As of the date of this announcement, the Board comprises: (i) Dr. Yifan Li, Dr. Kai Sun, Mr. Shaoqing Xiang and Ms. Cailian Yang as the executive Directors; and (ii) Ms. Yi Zhang, Mr. Jia Ren and Dr. Hui Wang as the independent non-executive Directors.

* *For identification purpose only*